Evidence map›Paper›PMID 42381352›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Larysa Panteleienko, Gargi Banerjee, Dermot Mallon, Edgar Chan, Simon Fandler-Höfler, Rupert Oliver, Victoria Harvey, Zane Jaunmuktane, John Collinge, David J Werring

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Larysa PanteleienkoDepartment of Translational Neuroscience and Stroke, Stroke Research Centre, UCL Queen Square Institute of Neurology, London, UK.ORCID https://orcid.org/0000-0002-7342-2488
Gargi BanerjeeInstitute of Prion Diseases, MRC Prion Unit at UCL, London, UK.
Dermot MallonNeuroradiological Academic Unit, UCL Queen Square Institute of Neurology, London, UK.
Edgar ChanNational Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
Simon Fandler-HöflerDepartment of Translational Neuroscience and Stroke, Stroke Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Rupert OliverNational Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
Victoria HarveyNational Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
Zane JaunmuktaneDivision of Neuropathology, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
John CollingeInstitute of Prion Diseases, MRC Prion Unit at UCL, London, UK.
David J WerringDepartment of Translational Neuroscience and Stroke, Stroke Research Centre, UCL Queen Square Institute of Neurology, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIatrogenic transmission of amyloid beta can cause cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD), but the relationship between these phenotypes is unclear.

methodsWe retrospectively analyzed standardized neuropsychological and neuroimaging data from 11 patients with iatrogenic CAA (iCAA). Brain MRI was assessed for medial temporal lobe atrophy (MTA), the posterior atrophy score for parietal atrophy, and global cortical atrophy (GCA).

resultsAll patients (mean age 42 ± 8.3 years) had childhood neurosurgery; 91% had confirmed cadaveric dura exposure. Six patients (55%) presented with intracerebral hemorrhage, and none showed MTA, parietal atrophy, or GCA at presentation. Over a median 5-year follow-up, 8/11 (73%) developed atrophy on at least one score, moderate to severe in three patients. Cognitive impairment was present in 9/11 (82%) at a median 3-year follow-up. AD was confirmed histopathologically in 2/4 (50%) examined cases. DISCUSSION: Progressive brain atrophy and cognitive impairment are common in iCAA, suggesting frequent co-existing neurodegeneration and possible AD pathology. Vigilance for cognitive decline may enable earlier identification and management.

Indexed as

BrainCerebral Amyloid AngiopathyAdultAlzheimer DiseaseAtrophyDisease ProgressionFemaleHumansIatrogenic DiseaseMagnetic Resonance ImagingMaleMiddle AgedNeuropsychological TestsRetrospective Studiesamyloid betacadaveric dura materiatrogenic Alzheimer's diseaseiatrogenic cerebral amyloid angiopathyneurosurgeryprion

Identifiers

PMID42381352
PMCPMC13319396

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.